Entering European Cannabis Markets: A Go-To-Market Framework

Key Insights

• Germany has the most advanced adult-use recreational cannabis framework in Europe, but the market culture is more pharmaceutical and business-driven than most US markets - assumptions from the US playbook do not transfer directly.
• The UK's novel foods framework makes CBD edibles and beverages nearly impossible to bring to market legally, requiring US brands to pursue alternative brand-building strategies to establish a presence before regulations shift.
• US cannabis brands should treat European market entry as a long-term strategic expansion, not a near-term solution to domestic market pressure - operational complexity is higher than most expect.
• Hemp and CBD brands can use European market entry as a brand-building bridge, establishing consumer awareness in markets like Germany and Czech Republic while waiting for recreational frameworks to mature.
• M&A activity is accelerating in European cannabis, with major Canadian LPs acquiring European pharmaceutical cannabis companies - signaling that institutional capital is positioning ahead of market maturation.

Expert Answers

[{What does entering the European cannabis market actually require from US brands?}

Entering European cannabis markets requires a country-specific regulatory strategy rather than a single pan-European approach. Each market operates under distinct rules: Germany has an adult-use recreational framework, the UK has a medical-only system with highly restrictive novel foods regulations for CBD, and Czech Republic is culturally ahead but still developing its regulatory path. Operational complexity - from licensing to distribution to banking - is significantly higher than most US operators anticipate. The guidance from JA Global is to approach Europe as a deliberate strategic expansion rather than a solution to domestic market challenges.

{Why is Germany the most important European cannabis market to understand?}

Germany has implemented one of the most developed adult-use recreational cannabis frameworks in Europe, making it the most commercially relevant starting point for international brands. The market culture is more pharmaceutical and business-driven than in many US markets, which affects how products need to be positioned and which local partnerships matter. Understanding those structural differences - and not assuming US market playbooks translate directly - is foundational to any German market strategy. Brands entering Germany need local regulatory expertise and distribution relationships before they can operate effectively.

{What is the novel foods framework and why does it complicate UK market entry?}

The UK's novel foods framework classifies any product containing CBD as a novel food, requiring separate authorization before legal sale. In practice, this makes it extremely difficult to bring CBD edibles and beverages to the UK market. Brands that want to build a UK presence before regulations become more permissive need to think creatively - establishing brand awareness through adjacent non-infused products, events, or adaptogenic formats first. The authorization pathway exists but is slow and has approved very few products to date.

{How should US cannabis brands evaluate European expansion?}

Europe should be evaluated as a long-term strategic opportunity, not a near-term revenue solution. The markets with the most regulatory progress - Germany and Czech Republic - have operational realities that are harder to navigate than US state markets. US brands with strong brand equity and capital can begin building European presence through hemp and CBD products, local partnerships, and industry events while waiting for recreational frameworks to develop further. Companies considering European expansion to offset domestic market difficulty should plan for a longer and more complex path than anticipated.

{What is driving M&A activity in European cannabis?}

The M&A activity in European cannabis is being driven by large Canadian licensed producers and international operators positioning ahead of regulatory maturation. The acquisition of Sanity Group - a German pharmaceutical cannabis company - by Organog, a major Canadian LP, signals that institutional capital sees long-term value in European markets and is moving to establish early positions. For US brands watching the space, these moves indicate that the window for early-stage positioning may be shorter than it currently appears.]

Webinar Highlights

00:00 – Introduction: Why European Cannabis Markets Matter Now

Jake Litke opens by framing Europe as a market he is watching closely, even as MediaJel's business remains primarily North American. His guest, Jill Agnello of JA Global, brings a practitioner's view of how international market entry actually works for cannabis brands - and what US companies consistently underestimate about the complexity involved.

08:00 – How Regulatory Frameworks Shape Market Entry

Jill walks through the regulatory landscape across key European markets - Germany, the UK, and Czech Republic - explaining how each country's framework determines which product categories are viable, what licensing is required, and how long it takes to realistically establish operations. The cultural dynamics that shape each market's regulatory pace are also covered.

18:00 – The Novel Foods Problem in the UK

A focused discussion on why CBD edibles and beverages are nearly impossible to bring to the UK market under the current novel foods classification system. Jill explains what alternative brand-building strategies are available for companies that want a UK presence before regulations shift, including adaptogenic products and non-infused brand activations.

28:00 – Who Is Already in Europe and What They're Doing

Jake asks which US brands are actively trying to build European brand equity. Jill covers the landscape - from celebrity-backed brands like Tyson exploring European presence to Canadian LPs making pharmaceutical acquisitions - and explains what is actually gaining traction versus what is still exploratory.

38:00 – When Europe Is Not the Right Answer

An honest segment on the limits of European expansion as a strategy for brands facing US market pressure. Jill explains why operational complexity in European markets is high enough that Europe should complement a strong North American foundation, not substitute for one, and what realistic expectations look like.

48:00 – M&A Activity and Where the Market Is Heading

The conversation closes on the growing M&A activity in European cannabis - including the Organog acquisition of Sanity Group - and what these moves signal about where institutional capital sees long-term value in the European market.

FAQ

Frequently Asked Questions

[ {What are the most accessible European cannabis markets for US brands?}

Germany and Czech Republic are currently the most developed markets from a regulatory standpoint, with Germany having the furthest-along adult-use recreational framework. The UK has the largest consumer base but the most complex regulatory environment for cannabis and CBD products. For US brands exploring entry, Germany is typically the starting point for evaluation, followed by Czech Republic for brands with hemp or CBD-led strategies. Local legal and operational partners are essential in all of these markets - there is no viable path to market without them.

{Why is it difficult to bring CBD products to the UK?}

The UK's novel foods framework classifies any food or beverage containing CBD as a novel food, requiring a separate authorization process before market entry. This authorization is difficult to obtain, and very few products have been approved. The framework effectively blocks most CBD edibles and beverages from legal sale, making the UK a challenging market for brands that rely on consumable formats. Building a UK presence often requires starting with non-ingestible formats or establishing brand equity through events and adjacent product categories first.

{Is European cannabis expansion a good hedge against US market volatility?}

European cannabis expansion is best treated as a strategic growth play, not a hedge against US market volatility. Operational complexity in European markets is high, local regulatory expertise is required in each country, and time-to-revenue is longer than most US operators expect. Brands struggling in the US are unlikely to find quick relief in Europe. For well-capitalized brands with a strong domestic foundation, Europe is a legitimate long-term opportunity worth building toward - just not a near-term fix.

{What US brands are currently building European cannabis presence?}

Celebrity and lifestyle-driven brands - including Tyson's cannabis venture - are among the US players exploring European market presence. Canadian licensed producers with existing European pharmaceutical relationships have been more active than most US companies so far. The brands gaining traction are those with capital, patience, and established local partnerships rather than those treating Europe as a rapid expansion play.

{What is JA Global and how do they help cannabis brands enter global markets?}

JA Global is a cannabis go-to-market strategy firm led by Jill Agnello, specializing in helping cannabis brands navigate international market entry. The firm works with licensed cannabis operators as well as hemp and CBD brands to develop market entry strategies, identify regulatory pathways, build local partnerships, and time entry for maximum viability. JA Global has particular depth in European markets including Germany, the UK, and Czech Republic.

{What conferences and networks are most useful for European cannabis market entry?}

Cannabis Europa and ICBC are the primary B2B conferences for European cannabis market participants and international companies looking to enter European markets. Tolman House, run by Alex Rogers, is an investment-focused networking group that gives cannabis companies access to European investors through a pitch-style format. These events provide market intelligence, relationship access, and real-time reads on where different European markets are heading from a regulatory and commercial standpoint. ]